U.S. Drug-Related Deaths
Soar, And It’s a Problem for Industry Too
David Taylor: "People need a reason to get up in the morning" |
Rising drug use and drug-related deaths are a concern for
many reasons. But a particular concern for economists is the impact of drugs on
the employment situation, and particularly on manufacturing industry. As of August, US manufacturing employment is
up a tiny 0.3% on a year ago. It’s up a slightly more heartening 4.4% on five
years ago. Yet, manufacturing job vacancies are up 3.6% in the past
year, and up 18% in the past five years. As of July, there were 379,000
manufacturing job vacancies, equivalent to 3% of manufacturing jobs. That’s the highest manufacturing job vacancy
rate since at least 2000. With unemployment still high in many areas and
millions of people voluntarily leaving the labor force, you’d expect people to
be jumping at the chance to fill those jobs. Yet, manufacturers across the
country report that it’s hard to fill those vacancies.
Drugs are a significant part of the reason. According to the
Pennsylvania Manufacturers Association (PMA), about one
third of manufacturing job applicants can’t pass a drug test. That
Pennsylvania survey is borne out by evidence from other states. According to an
article
last May in the New York Times, manufacturers in the state of Georgia are
suffering from the same problem, so much so that Governor Nathan Deal promised
to develop a plan to help. He told the Times: “the number one reason they can’t
hire enough workers is they can’t find enough people to pass a drug test.” The
CEO of an Indiana-based manufacturer of products for recreational vehicles told
the local newspaper that “a majority of applicants in the current environment
cannot pass…the controlled substance requirements.”
Source: U.S. Centers For Disease Control |
The drugs problem is due to a range of drugs, but experts
attribute the rise of drug deaths to the strange story of the rise of
OxyContin, a synthetic painkiller introduced in 1996 by Purdue Pharmaceuticals
as an innovative cousin of morphine that promised pain relief for twelve hours
from a single pill. According to an article
in the National Review, by 2004, 2.4 million Americans were taking OxyContin.
Prescriptions can cost $600 for a bottle of pills, but most of the cost is paid
by insurance companies. The drug was most popular with white males in rustbelt
and Appalachian areas, leading to the nickname “hillbilly heroin.” According to
the L.A. Times, back in the 1990s Purdue launched the drug
with a $200 million marketing budget while doubling its salesforce to 600. Even
Purdue was surprised by their success: it became a billion-dollar drug within
five years, and to date, the drug has generated $31 billion in revenue. Purdue had legal skirmishes over misleading
marketing of the drug; in 2007, it had its Wells Fargo moment, pleading guilty
to a felony charge and paying a fine of $635 million (about 2% of Purdue’s
cumulative revenue from the drug, making it a minor cost of doing business). OxyContin’s highly addictive properties have led
to a significant number of overdoses and deaths.
Source: Bureau of Labor Statistics |
Following political and medical pressure, Purdue changed the
formulation in 2010 to make it harder to crush the pills and snort them.
Experts say that led to an unexpected development: OxyContin users turned to
heroin, which became readily available through a growing network of Mexico-based
heroin suppliers. Improved production methods have driven down the price of
heroin. On top of that, a new synthetic drug, fentanyl, said to be hundreds of
times more potent than heroin, is often mixed in with heroin by drug dealers.
Fentanyl is apparently added in unpredictable quantities, making a heroin shot
more of a game of Russian Roulette than it used to be. Fentanyl is the drug
that killed pop singer Prince. It has led to a rash of deaths recently in
Cincinnati, New Hampshire and elsewhere in the U.S.
It’s a very worrying trend, because we have highly focused
companies like Purdue that are financially incentivized to increase the number
of people using addictive drugs, combined with technological progress making
drugs, legal and illegal, cheaper and easier to obtain. Meanwhile, the number
of attractive, well-paid jobs for those who are not highly educated is shrinking,
leading more people, particularly in the white non-college-educated
demographic, to turn to drugs as an escape. I spoke to David Taylor, president
of the Pennsylvania Manufacturers Association. He believes the growing drug
problem, including both prescription and illegal drugs, reflects a decline in
the work ethic and the attractiveness of work for millions of Americans.
“People need a reason to get up each morning, they need a sense of oneself that
can only come from applying one’s talents and working with other people,” he
said. “And instead, we’re making it easier for people to give up and disengage
from the realities of life.” Two other
signs of the same problem are the dramatic rise in Americans claiming federal
disability benefits, and a recent study that found that 22% of young
non-college educated men have not worked in the past year. The study found that
these men spend some 75% of the time they would have been working playing video
games instead.
There are no simple solutions. The decline of the work ethic,
the loss of well-paying jobs for those not highly educated, the rise of drugs,
are each enormously complex problems. Unfortunately, little of this has been
discussed in the current presidential election campaign, which has been
dominated by emotionally charged personality issues and simplistic platitudes.
So not only do we end up knowing little about what either candidate thinks
about these important issues, but the candidates themselves are missing a
chance to raise awareness and educate the American people on issues that will
affect them for many years to come.
No comments:
Post a Comment